Plaque array methods and compositions for forming and detecting plaques
AssigneePlaxgen Inc
InventorShanmugavel Madasamy
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for the in vitro formation of an array of plaque particles for use in biological assays, diagnosis, drug discovery and drug development. More specifically, the embodiments described herein relate to the in vitro synthesis of plaque particles when treated with biofluids and identification of such plaque particles by a variety of detection systems. In particular, the resulting in vitro plaque particles resemble atherosclerotic and amyloid plaques. The plaque embodiments described may be used to enable rapid, sensitive and/or efficient drug discovery, medical diagnostics and patient stratification.
Claims30
A method of detecting plaque particle formation in a subject, the method comprising:
- a. preparing at least one plaque aggregate or self-formed plaque particle in vitro wherein the plaque aggregate or self-formed plaque particle is linked to a detectable label;
- b. contacting a biological sample from the subject with the at least one plaque aggregate or self-formed plaque particle;
- and
- c. following step b, employing a device to detect the detectable label.
A method for detecting plaque particle formation in a subject, comprising:
- a. preparing at least one plaque aggregate or self-formed plaque particle;
- b. contacting a biological sample from the subject with the at least one plaque aggregate or self-formed plaque particle;
- c. contacting the product of step b with detectable label or an antibody-linked detectable label;
- and
- d. following step c, employing a device to detect the detectable label.
A method of screening a test agent comprising:
- a. preparing at least one plaque aggregate or self-formed plaque particle in vitro wherein the plaque aggregate or self-formed plaque particle is linked to a detectable label;
- b. contacting the at least one plaque aggregates or self-formed plaque particles linked to a detectable label with at least one test agents;
- c. following step b, employing a device to detect the detectable label.
A method of screening a test agent comprising:
- a. preparing at least one plaque aggregate or self-formed plaque particle in vitro wherein the plaque aggregate or self-formed plaque particle is linked to a detectable label;
- b. culturing mammalian cells with plaque aggregates or self-formed plaque particles linked to a detectable label wherein the mammalian cells express morphologic changes, pathological symptoms, cell adhesion molecules, cytokines and or apoptosis, inflammation;
- c. contacting the mammalian cells with at least one test agents;
- and
- d. identifying test agents that prevent or lessen the formation of pathological symptoms or morphological changes in the cells.
A method of biomarker identification in a subject, the method comprising:
- a. preparing at least one plaque aggregate or self-formed plaque particle in vitro wherein the plaque aggregate or self-formed plaque particle is linked to a detectable label;
- b. contacting a biological sample from the subject with the at least one plaque aggregate or self-formed plaque particle;
- and
- c. following step b, identification of protein or antibody or metabolite or substance from the biological sample that contributed to accelerated plaque particle formation using proteomics or mass spectrometry analysis or the like.
Dependencies are inferred from the claim text.